Director/PDMR Shareholding
Summary by AI BETAClose X
TheraCryf plc
("TheraCryf", the "Company" or the "Group")
Share Purchase by a Director
Alderley Park, UK - 16 October 2025: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, announces that Northern Standard Limited, a company that Non-Executive Director, Ed Wardle, has a 49 per cent interest in purchased 7,342,296 ordinary shares of 0.25 pence each in the Company ("Ordinary Shares") on 14 October 2025 at a price of £0.00175 and now owns 430,069,568 Ordinary Shares.
As a result, Mr Wardle is deemed to have an interest in 430,069,568 Ordinary Shares, representing 20.01 per cent of the Company's issued Ordinary Shares.
Enquiries
|
|
||||||||
|
|
|
About TheraCryf plc
TheraCryf is the clinical stage drug development company focussing on brain disorders. The Company has a broad clinical and preclinical pipeline in indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma* and neurodevelopmental disorders [*orphan indication].
The Company's strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation. It also has a number of industry partnerships with companies, including Stalicla SA, in neurodevelopmental disorders. The Company has sourced know-how for programmes from companies such as Shire (now Takeda).
TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.
The Company has its headquarters and registered office at Alderley Park, Cheshire. It is quoted on AIM in London and trades under the ticker symbol TCF.
|
1. |
Details of PDMR / person closely associated with them ("PCA") |
|||||||||
|
a) |
Name |
Edward James Norman Wardle |
||||||||
|
b) |
Position / status |
Non Executive Director |
||||||||
|
c) |
Initial notification / amendment |
Initial notification |
||||||||
|
2. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||
|
a) |
Description of the financial instrument |
Theracryc PLC |
||||||||
|
b) |
Nature of the transaction |
Acquisition of ordinary shares by Northern Standard Limited, a company that Edward James Norman Wardle has 49% ownership of |
||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||
|
d) |
Aggregated information - Aggregated volume - Price |
See above |
||||||||
|
e) |
Date of the transaction |
14 October 2025 |
||||||||
|
f) |
Place of the transaction |
Outside a trading venue |
||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund